Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Dosing of Nivolumab plus Ipilimumab in Child-Pugh B Hepatocellular Carcinoma
NCT07689175Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2026
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in hepatocellular carcinoma (HCC), sponsored by UT Southwestern Medical Center. Started Aug 2026; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07689175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689175.